Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587730 · ClinicalTrials.gov registry record · Phase 2
Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 608
- Enrollment target
NCT00587730: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00587730 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 608 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (357% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587730, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 608 participants
- Enrollment target
Study Summary
The accuracy of stress single photon emission computed tomography (SPECT) is limited by imaging artifacts, many of which are caused by soft tissue attenuation. A recent multicenter study performed by our laboratory comparing 7 commercially available attenuation correction (AC) camera systems in a cardiac phantom showed the best performance with the GE Hawkeye (a hybrid gamma camera-CT scanner) and the University of Michigan M-step (unique feature a camera orbit of 360˚ versus the usual 180˚) systems. In this study we will combine the strengths of these two systems (GE Hawkeye AC system and 360˚ camera orbit) to test the accuracy of this imaging system in a population of 400 consecutive patients undergoing clinically indicated stress SPECT. These patients will undergo SPECT imaging both with conventional methodology and the GE Hawkeye system. The conventional study will be interpreted and reported in the usual clinical fashion. The GE Hawkeye images will be interpreted independently by 2 observers blinded to the results of conventional imaging and will not be reported clinically. The primary study hypothesis is that AC will substantially reduce attenuation artifacts (mild fixed defects) without reducing the accuracy of either normal studies or myocardial infarction (MI). Clinical data and noninvasive test results (history of MI, electrocardiogram, and gated wall motion) will be used to distinguish defects which represent attenuation (false-positive) versus those due to MI (true-positive).
Interventions
- DEVICE GE Attenuation Corrected Hawkeye Camera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2001-07 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Why NCT00587730 stopped before completion
NCT00587730 is an interventional study that assigns participants to a tested intervention. The registered 608 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (357% higher).
The record links to 0 conditions, and to 1 intervention - of which GE Attenuation Corrected Hawkeye Camera is the first listed.
NCT00587730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00587730 about?
NCT00587730 is a clinical study titled "Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System". The accuracy of stress single photon emission computed tomography (SPECT) is limited by imaging artifacts, many of which are caused by soft tissue attenuation. A recent multicenter study performed by our laboratory comparing 7 commercially available attenuation correction (AC) camera systems in a ca...
What is the current status of trial NCT00587730?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 608 participants. The study started on 2001-07. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00587730?
The interventions under investigation include: GE Attenuation Corrected Hawkeye Camera (DEVICE).
Who is sponsoring clinical trial NCT00587730?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00587730's enrollment target sits among peer trials
608 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia